Pregabalin in workers' compensation claims NSW

Understanding medication appropriateness and SIRA guidance for gabapentinoid prescribing

Published 2026-04-03

Pregabalin (sold as Lyrica) is a gabapentinoid commonly prescribed for neuropathic pain in workers compensation claims. If you manage NSW workers compensation, you've likely encountered claims where claimants are on pregabalin, often at high doses and often with questions about appropriateness.

Understanding when pregabalin is appropriate, what SIRA (State Insurance Regulatory Authority) expects, and how to manage these prescriptions in your claims is essential for effective medication governance.

What is pregabalin?

Pregabalin is an anticonvulsant and anxiolytic medication used primarily for neuropathic pain conditions. It's commonly prescribed for:

• Neuropathic pain (nerve pain, post-herpetic neuralgia, diabetic neuropathy)
• Anxiety disorders
• Fibromyalgia
• Post-operative pain

In workers compensation claims, pregabalin is often prescribed for neuropathic pain arising from the workplace injury or for anxiety related to ongoing pain or incapacity.

Why pregabalin is common in workers comp claims

Pregabalin is frequently used in workers compensation because:

• Many workplace injuries result in nerve pain, which responds to gabapentinoids
• It's considered safer than opioids for long-term pain management
• It can help with anxiety and sleep, common in claims with prolonged incapacity
• It's readily available and commonly prescribed

However, pregabalin has significant drawbacks for insurance claims: high cost, potential for dose escalation, side effects that can limit function, and questions about long-term efficacy.

SIRA guidance on pregabalin

The State Insurance Regulatory Authority in NSW has issued guidance on pregabalin and gabapentinoids in workers compensation. Key points include:

• Evidence base: Evidence for gabapentinoids in treating pain is limited. SIRA encourages insurers to scrutinize whether the evidence supports their use in individual claims.
• Neuropathic pain indication: Gabapentinoids may be appropriate for confirmed neuropathic pain, but evidence for other pain types is weaker.
• Dose limits: There's limited evidence supporting high doses. Doses beyond therapeutic ranges may not be evidence-based.
• Duration: Long-term efficacy is not well-established. Regular review of whether the medication is actually helping is recommended.
• Combination therapy: Combining gabapentinoids with opioids increases side effect risk and may not be evidence-based.

In essence, SIRA's position is: pregabalin can be appropriate in certain circumstances, but insurer scrutiny is warranted. You should expect evidence that the medication is necessary and effective before funding long-term high-dose therapy.

Clinical assessment of pregabalin appropriateness

When evaluating pregabalin prescription in a claim, consider:

Pharmacy review for pregabalin assessment

When you have questions about pregabalin appropriateness in a claim, refer for pharmacy review. The pharmacist will assess:

• Whether the indication aligns with evidence for pregabalin use
• Whether dose is appropriate for the indication
• Whether the claimant has benefited from the medication
• Whether side effects are limiting function
• Whether alternative treatments or dose reductions might be beneficial
• Whether continuing pregabalin aligns with claims goals (return to work, functional improvement)

Pharmacist assessment provides evidence-based analysis of whether pregabalin should continue, be modified, or be replaced.

Common scenarios and management

Scenario 1: High-dose pregabalin without clear benefit

Claimant is on 600mg daily (or higher), has been on it for months, but reports minimal pain improvement. Pharmacy review likely recommends trial of dose reduction or discontinuation to assess whether the claimant is actually benefiting. If claimant feels no worse at lower dose, the reduction is justified and saves claim costs.

Scenario 2: Pregabalin combined with opioids

Claimant on pregabalin and oxycodone is severely sedated and unable to work. Pharmacy review assesses whether both medications are necessary or whether one could be stopped/reduced. Often, deprescribing one medication allows better function without the other.

Scenario 3: Pregabalin for non-neuropathic pain

Claimant with straightforward musculoskeletal pain is prescribed pregabalin without clear neuropathic indication. Pharmacy review documents that the indication doesn't align with evidence, supporting your position that alternative treatments might be more appropriate.

Working with providers on pregabalin

When you question pregabalin prescribing, frame inquiries constructively:

• "We're reviewing medication appropriateness in this claim. Can you explain your clinical rationale for pregabalin at this dose? Is the claimant experiencing confirmed neuropathic pain?"
• "The claimant has been on pregabalin for [timeframe] without improvement in function. Would you be open to trialing a dose reduction to see whether the claimant can function better without sedation?"
• "We're concerned about combined sedation from pregabalin and opioids. Would you consider reducing one medication to see whether function improves?"

Providers who understand you're seeking optimal outcomes are more likely to engage in thoughtful discussion about medication management.

SIRA alignment and defensibility

If you're questioning pregabalin prescribing in NSW claims, you're aligned with SIRA's expectations. Documenting your assessment and rationale (preferably through pharmacy review) makes your position defensible should it be challenged.

You're not denying necessary medication. You're ensuring medication is evidence-based, beneficial, and appropriate for the claim.